|
|
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Isradipine#Administration and Monitoring]] |
| | |
| | |
| | |
| The dosage of Isradipine should be individualized.
| |
| | |
| The recommended initial dose of Isradipine is 2.5 mg b.i.d. alone or in combination with a [[thiazide diuretic]]. An antihypertensive response usually occurs within 2-3 hours. Maximal response may require 2-4 weeks. If a satisfactory reduction in blood pressure does not occur after this period, the dose may be adjusted in increments of 5 mg/day at 2-4 week intervals up to a maximum of 20 mg/day. Most patients, however, show no additional response to doses above 10 mg/day, and adverse effects are increased in frequency above 10 mg/day.
| |
| | |
| The bioavailability of Isradipine (increased AUC) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, the starting dose should still be 2.5 mg b.i.d. in these patients.
| |
| | |
| | |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| | |
| [[Category:Drugs]]
| |